Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)

Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.

Guardado en:

Detalles Bibliográficos
Autores principales:	Varbanova V., Anastasova-Postadzhiyan A., Nedeva A., Nikolov I., Kindekov I., Kuyumdzhieva Y., Petkova N., Vikentieva E., Lubomir M., Raynov J.
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2020
Materias:	azacytidine mds aml cmml-2 Medicine R
Acceso en línea:	https://doaj.org/article/68c13731127941479f89d5929d224e01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:68c13731127941479f89d5929d224e01
record_format	dspace
spelling	oai:doaj.org-article:68c13731127941479f89d5929d224e012021-12-02T14:29:40ZOutcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)0324-175010.2478/amb-2020-0043https://doaj.org/article/68c13731127941479f89d5929d224e012020-11-01T00:00:00Zhttps://doi.org/10.2478/amb-2020-0043https://doaj.org/toc/0324-1750Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.Varbanova V.Anastasova-Postadzhiyan A.Nedeva A.Nikolov I.Kindekov I.Kuyumdzhieva Y.Petkova N.Vikentieva E.Lubomir M.Raynov J.Sciendoarticleazacytidinemdsamlcmml-2MedicineRENActa Medica Bulgarica, Vol 47, Iss 4, Pp 38-43 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	azacytidine mds aml cmml-2 Medicine R
spellingShingle	azacytidine mds aml cmml-2 Medicine R Varbanova V. Anastasova-Postadzhiyan A. Nedeva A. Nikolov I. Kindekov I. Kuyumdzhieva Y. Petkova N. Vikentieva E. Lubomir M. Raynov J. Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
description	Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.
format	article
author	Varbanova V. Anastasova-Postadzhiyan A. Nedeva A. Nikolov I. Kindekov I. Kuyumdzhieva Y. Petkova N. Vikentieva E. Lubomir M. Raynov J.
author_facet	Varbanova V. Anastasova-Postadzhiyan A. Nedeva A. Nikolov I. Kindekov I. Kuyumdzhieva Y. Petkova N. Vikentieva E. Lubomir M. Raynov J.
author_sort	Varbanova V.
title	Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
title_short	Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
title_full	Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
title_fullStr	Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
title_full_unstemmed	Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
title_sort	outcome after azacitidine treatment in patients with high-risk myeolodysplastic syndrome, chronic myelomonocytic leukemia type 2 and acute myeloid leukemia – a single center experience (preliminary data)
publisher	Sciendo
publishDate	2020
url	https://doaj.org/article/68c13731127941479f89d5929d224e01
work_keys_str_mv	AT varbanovav outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata AT anastasovapostadzhiyana outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata AT nedevaa outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata AT nikolovi outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata AT kindekovi outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata AT kuyumdzhievay outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata AT petkovan outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata AT vikentievae outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata AT lubomirm outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata AT raynovj outcomeafterazacitidinetreatmentinpatientswithhighriskmyeolodysplasticsyndromechronicmyelomonocyticleukemiatype2andacutemyeloidleukemiaasinglecenterexperiencepreliminarydata
_version_	1718391195437105152

Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)

Ejemplares similares